The Effect of LY333531 on Protein in the Urine in Patients With Type 2 Diabetes - Tabular View

Tracking Information
First Received Date ^ICMJE	August 20, 2002
Last Updated Date	July 18, 2006
Start Date ^ICMJE
Primary Completion Date
Current Primary Outcome Measures ^ICMJE
Original Primary Outcome Measures ^ICMJE
Change History	Complete list of historical versions of study NCT00044148 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures ^ICMJE
Original Secondary Outcome Measures ^ICMJE

Descriptive Information
Brief Title ^ICMJE	The Effect of LY333531 on Protein in the Urine in Patients With Type 2 Diabetes
Official Title ^ICMJE
Brief Summary	The purpose of this study are to determine 1) Whether Ly333531 can reduce urinary albumin/creatinine excretion in patients with Type II diabetes and persistent albuminuria 2) Whether LY333531 reduces urinary TGF-B, 3) the safety of LY333531 and any side effects that may be associated with it.
Detailed Description
Study Phase	Phase II
Study Type ^ICMJE	Interventional
Study Design ^ICMJE	Treatment
Condition ^ICMJE	Diabetic Nephropathy
Intervention ^ICMJE	Drug: LY333531
Study Arms / Comparison Groups
Publications *
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Completed
Enrollment ^ICMJE
Completion Date
Primary Completion Date
Eligibility Criteria ^ICMJE	Inclusion Criteria: Type 2 diabetes mellitus Greater than or equal to 30 years of age Albumin to Creatinine ratio (greater than 200 mg/g and less than 2000 mg/g) 4)Without language barrier. Exclusion Criteria: Serum Creatinine greater than 2.0 mg/dl males or greater than 1.7 mg/dl females B/P greater than 150 systolic and greater than 90 diastolic Hemoglobin Alc greater than 11% Liver Function Tests 2 times upper limit of normal Poor medical or psychiatric risk.
Gender	Both
Ages	30 Years and older
Accepts Healthy Volunteers	Yes
Contacts ^ICMJE	Contact information is only displayed when the study is recruiting subjects
Location Countries ^ICMJE	United States

Administrative Information
NCT ID ^ICMJE	NCT00044148
Responsible Party
Study ID Numbers ^ICMJE	6249, B7A-MC-MBDA
Study Sponsor ^ICMJE	Eli Lilly and Company
Collaborators ^ICMJE
Investigators ^ICMJE
Information Provided By	Eli Lilly and Company
Verification Date	July 2006
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP